512 related articles for article (PubMed ID: 28288579)
1. The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease.
Yarnoff BO; Hoerger TJ; Simpson SK; Leib A; Burrows NR; Shrestha SS; Pavkov ME;
BMC Nephrol; 2017 Mar; 18(1):85. PubMed ID: 28288579
[TBL] [Abstract][Full Text] [Related]
2. Strategies and cost-effectiveness evaluation of persistent albuminuria screening among high-risk population of chronic kidney disease.
Wang H; Yang L; Wang F; Zhang L
BMC Nephrol; 2017 Apr; 18(1):135. PubMed ID: 28420333
[TBL] [Abstract][Full Text] [Related]
3. Screening for chronic kidney disease in Canadian indigenous peoples is cost-effective.
Ferguson TW; Tangri N; Tan Z; James MT; Lavallee BDA; Chartrand CD; McLeod LL; Dart AB; Rigatto C; Komenda PVJ
Kidney Int; 2017 Jul; 92(1):192-200. PubMed ID: 28433383
[TBL] [Abstract][Full Text] [Related]
4. A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening.
Hoerger TJ; Wittenborn JS; Segel JE; Burrows NR; Imai K; Eggers P; Pavkov ME; Jordan R; Hailpern SM; Schoolwerth AC; Williams DE;
Am J Kidney Dis; 2010 Mar; 55(3):463-73. PubMed ID: 20116910
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Pneumococcal Vaccination Among Patients With CKD in the United States.
Ishigami J; Padula WV; Grams ME; Chang AR; Jaar B; Gansevoort RT; Bridges JFP; Kovesdy CP; Uchida S; Coresh J; Matsushita K
Am J Kidney Dis; 2019 Jul; 74(1):23-35. PubMed ID: 30898360
[TBL] [Abstract][Full Text] [Related]
6. Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland.
Kessler R; Keusch G; Szucs TD; Wittenborn JS; Hoerger TJ; Brügger U; Wieser S
Swiss Med Wkly; 2012; 142():w13508. PubMed ID: 22307760
[TBL] [Abstract][Full Text] [Related]
7. Cost-utility analysis of the National Health Screening Program for chronic kidney disease in Korea.
Go DS; Kim SH; Park J; Ryu DR; Lee HJ; Jo MW
Nephrology (Carlton); 2019 Jan; 24(1):56-64. PubMed ID: 29206319
[TBL] [Abstract][Full Text] [Related]
8. Development of the simulation-based German albuminuria screening model (S-GASM) for estimating the cost-effectiveness of albuminuria screening in Germany.
Kairys P; Frese T; Voigt P; Horn J; Girndt M; Mikolajczyk R
PLoS One; 2022; 17(1):e0262227. PubMed ID: 34986199
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of home-based screening of the general population for albuminuria to prevent progression of cardiovascular and kidney disease.
Pouwels XGLV; van Mil D; Kieneker LM; Boersma C; van Etten RW; Evers-Roeten B; Heerspink HJL; Hemmelder MH; Langelaan MLP; Thelen MHM; Gansevoort RT; Koffijberg H
EClinicalMedicine; 2024 Feb; 68():102414. PubMed ID: 38299045
[TBL] [Abstract][Full Text] [Related]
10. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.
Boersma C; Gansevoort RT; Pechlivanoglou P; Visser ST; van Toly FF; de Jong-van den Berg LT; de Jong PE; Postma MJ;
Clin Ther; 2010 Jun; 32(6):1103-21. PubMed ID: 20637965
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of multidisciplinary care in mild to moderate chronic kidney disease in the United States: A modeling study.
Lin E; Chertow GM; Yan B; Malcolm E; Goldhaber-Fiebert JD
PLoS Med; 2018 Mar; 15(3):e1002532. PubMed ID: 29584720
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of primary screening for CKD: a systematic review.
Komenda P; Ferguson TW; Macdonald K; Rigatto C; Koolage C; Sood MM; Tangri N
Am J Kidney Dis; 2014 May; 63(5):789-97. PubMed ID: 24529536
[TBL] [Abstract][Full Text] [Related]
13. Population-Wide Screening for Chronic Kidney Disease : A Cost-Effectiveness Analysis.
Cusick MM; Tisdale RL; Chertow GM; Owens DK; Goldhaber-Fiebert JD
Ann Intern Med; 2023 Jun; 176(6):788-797. PubMed ID: 37216661
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis.
Howard K; White S; Salkeld G; McDonald S; Craig JC; Chadban S; Cass A
Value Health; 2010; 13(2):196-208. PubMed ID: 19878493
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of screening for chronic kidney disease in the general adult population: a systematic review.
Yeo SC; Wang H; Ang YG; Lim CK; Ooi XY
Clin Kidney J; 2024 Jan; 17(1):sfad137. PubMed ID: 38186904
[TBL] [Abstract][Full Text] [Related]
16. Screening for proteinuria in US adults: a cost-effectiveness analysis.
Boulware LE; Jaar BG; Tarver-Carr ME; Brancati FL; Powe NR
JAMA; 2003 Dec; 290(23):3101-14. PubMed ID: 14679273
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of screening for oral cancer in primary care.
Speight PM; Palmer S; Moles DR; Downer MC; Smith DH; Henriksson M; Augustovski F
Health Technol Assess; 2006 Apr; 10(14):1-144, iii-iv. PubMed ID: 16707071
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of chronic kidney disease mass screening test in Japan.
Kondo M; Yamagata K; Hoshi SL; Saito C; Asahi K; Moriyama T; Tsuruya K; Yoshida H; Iseki K; Watanabe T
Clin Exp Nephrol; 2012 Apr; 16(2):279-91. PubMed ID: 22167460
[TBL] [Abstract][Full Text] [Related]
19. Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients.
Nguyen HV; Bose S; Finkelstein E
BMC Nephrol; 2016 Apr; 17(1):45. PubMed ID: 27121505
[TBL] [Abstract][Full Text] [Related]
20. Health benefits and costs of screening for colorectal cancer in people on dialysis or who have received a kidney transplant.
Wong G; Li MW; Howard K; Hua DK; Chapman JR; Bourke M; Turner R; Tong A; Craig JC
Nephrol Dial Transplant; 2013 Apr; 28(4):917-26. PubMed ID: 23182812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
